Pamrevlumab for the treatment of idiopathic pulmonary fibrosis
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
INTRODUCTION: The two available therapies for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, slow down but do not halt IPF progression. As such, in the last few years several agents with specific molecular targets have been investigated to find a cure forIPF. Pamrevlumab, a recombinant human antibody that binds to connective tissue growth factor (CTGF) has emerged as a potential therapy for IPF and has advanced to phase 3 clinical trials. AREAS COVERED: The authors offer a backdrop to the current IPF treatment market and describe the chemistry, pharmacokinetics and pharmacodynamics of pamrevlumab. They summarize the preclinical and early clinical evidence on pamrevlumab and propose ways of progressing this agent further as a potential IPF treatment. EXPERT OPINION: Pamrevlumab was effective and safe in patients in a placebo-controlled phase 2 trial, demonstrating its potential to become an alternative therapeutic option for IPF; however, the feasibility of intravenous administration in clinical practice may be a hurdle to its use as a first-line treatment. Further studies are necessary to assess its effects when administered with pirfenidone or nintedanib and this could open up a new era of combined therapeutic approaches for IPF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unfortunately, a phase 3 trial (ZEPHYRUS-1) that compared pamrevlumab to placebo failed to find a difference between the two groups at 48 weeks in the mean decline in FVC [71,72].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [71]
In the citing paper
“Despite very favorable phase 2 trials in IPF patients, its phase 3 trial failed to show important improvements and the drug was abandoned for IPF [71].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [71]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 40 · Cited by 59
Research works printed but not linked: 4
- Fisher M, 2017, J Manag Care Spec Pharm, 23, S17
- 10.1016/S2213-2600(19)30262-0. · DOI · Paper page
- Gorina E, 2018, Am J Respir Crit Care Med, 8, 25
- Flaherty KR, 2019, N Engl J Med, 382, 779
Metadata
- Authors
- Sgalla, G., Franciosa, C., Simonetti, J., & Richeldi, L.
- Affiliations
- Agostino Gemelli University Polyclinic (IT)
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Sgalla, Giacomo
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2020-06-07
- Volume
- 29
- Issue
- 8
- Pages
- 771-777
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W3027885648
- Cited by
- 59
- References
- 40
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 11 · 2023: 19 · 2022: 10 · 2021: 8 · 2020: 3
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- idiopathic pulmonary fibrosis, connective tissue growth factor, monoclonal antibodies, pirfenidone, nintedanib, combination therapy, pharmacokinetics, pharmacodynamics, intravenous administration, antifibrotic therapy
- MeSH terms
- Animals, Humans, Indoles, Pyridones, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis, Connective Tissue Growth Factor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1080/13543784.2020.1773790
- The paper
- Sgalla, G., Franciosa, C., Simonetti, J., & Richeldi, L. (2020). Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2020.1773790
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.